These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 22549243)
1. In vitro the behaviors of metastasis with suppression of VEGF in human bone metastatic LNCaP-derivative C4-2B prostate cancer cell line. Yang L; You S; Kumar V; Zhang C; Cao Y J Exp Clin Cancer Res; 2012 May; 31(1):40. PubMed ID: 22549243 [TBL] [Abstract][Full Text] [Related]
2. Aromatic Hydrocarbon Receptor Suppresses Prostate Cancer Bone Metastasis Cells-Induced Vasculogenesis of Endothelial Progenitor Cells under Hypoxia. Huang S; Guo Y; Jacobi A; Li Z; Huang S; He J; Liu X; Tang Y Cell Physiol Biochem; 2016; 39(2):709-20. PubMed ID: 27448695 [TBL] [Abstract][Full Text] [Related]
3. Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. Fu Z; Smith PC; Zhang L; Rubin MA; Dunn RL; Yao Z; Keller ET J Natl Cancer Inst; 2003 Jun; 95(12):878-89. PubMed ID: 12813171 [TBL] [Abstract][Full Text] [Related]
4. The role of vascular endothelial growth factor in the tissue specific in vivo growth of prostate cancer cells. Krupski T; Harding MA; Herce ME; Gulding KM; Stoler MH; Theodorescu D Growth Factors; 2001; 18(4):287-302. PubMed ID: 11519827 [TBL] [Abstract][Full Text] [Related]
5. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma. Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514 [TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Dai J; Kitagawa Y; Zhang J; Yao Z; Mizokami A; Cheng S; Nör J; McCauley LK; Taichman RS; Keller ET Cancer Res; 2004 Feb; 64(3):994-9. PubMed ID: 14871830 [TBL] [Abstract][Full Text] [Related]
7. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor. Balbay MD; Pettaway CA; Kuniyasu H; Inoue K; Ramirez E; Li E; Fidler IJ; Dinney CP Clin Cancer Res; 1999 Apr; 5(4):783-9. PubMed ID: 10213213 [TBL] [Abstract][Full Text] [Related]
8. Cellular interactions in the tropism of prostate cancer to bone. Sikes RA; Nicholson BE; Koeneman KS; Edlund NM; Bissonette EA; Bradley MJ; Thalmann GN; Cecchini MG; Pienta KJ; Chung LW Int J Cancer; 2004 Jul; 110(4):497-503. PubMed ID: 15122581 [TBL] [Abstract][Full Text] [Related]
9. Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer. Anai S; Sakamoto N; Sakai Y; Tanaka M; Porvasnik S; Urbanek C; Cao W; Goodison S; Rosser CJ Urol Oncol; 2011; 29(4):421-9. PubMed ID: 19576799 [TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Kitagawa Y; Dai J; Zhang J; Keller JM; Nor J; Yao Z; Keller ET Cancer Res; 2005 Dec; 65(23):10921-9. PubMed ID: 16322239 [TBL] [Abstract][Full Text] [Related]
11. Bevacizumab terminates homeobox B9-induced tumor proliferation by silencing microenvironmental communication. Hoshino Y; Hayashida T; Hirata A; Takahashi H; Chiba N; Ohmura M; Wakui M; Jinno H; Hasegawa H; Maheswaran S; Suematsu M; Kitagawa Y Mol Cancer; 2014 May; 13():102. PubMed ID: 24885802 [TBL] [Abstract][Full Text] [Related]
12. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Lin DL; Tarnowski CP; Zhang J; Dai J; Rohn E; Patel AH; Morris MD; Keller ET Prostate; 2001 May; 47(3):212-21. PubMed ID: 11351351 [TBL] [Abstract][Full Text] [Related]
13. Pristimerin Inhibits Prostate Cancer Bone Metastasis by Targeting PC-3 Stem Cell Characteristics and VEGF-Induced Vasculogenesis of BM-EPCs. Huang S; He P; Peng X; Li J; Xu D; Tang Y Cell Physiol Biochem; 2015; 37(1):253-68. PubMed ID: 26302893 [TBL] [Abstract][Full Text] [Related]
14. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Thalmann GN; Sikes RA; Wu TT; Degeorges A; Chang SM; Ozen M; Pathak S; Chung LW Prostate; 2000 Jul; 44(2):91-103 Jul 1;44(2). PubMed ID: 10881018 [TBL] [Abstract][Full Text] [Related]
15. Genetic delivery of the murine equivalent of bevacizumab (avastin), an anti-vascular endothelial growth factor monoclonal antibody, to suppress growth of human tumors in immunodeficient mice. Watanabe M; Boyer JL; Hackett NR; Qiu J; Crystal RG Hum Gene Ther; 2008 Mar; 19(3):300-10. PubMed ID: 18324912 [TBL] [Abstract][Full Text] [Related]
16. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Joseph IB; Isaacs JT Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270 [TBL] [Abstract][Full Text] [Related]
17. Butein suppresses the expression of nuclear factor-kappa B-mediated matrix metalloproteinase-9 and vascular endothelial growth factor in prostate cancer cells. Moon DO; Choi YH; Moon SK; Kim WJ; Kim GY Toxicol In Vitro; 2010 Oct; 24(7):1927-34. PubMed ID: 20696233 [TBL] [Abstract][Full Text] [Related]
18. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer. Zhou Y; Li S; Li J; Wang D; Li Q Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819 [TBL] [Abstract][Full Text] [Related]
19. Hypoxia increases VEGF-A production by prostate cancer and bone marrow stromal cells and initiates paracrine activation of bone marrow endothelial cells. Muir C; Chung LW; Carson DD; Farach-Carson MC Clin Exp Metastasis; 2006; 23(1):75-86. PubMed ID: 16826426 [TBL] [Abstract][Full Text] [Related]
20. The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops. Adamcic U; Skowronski K; Peters C; Morrison J; Coomber BL Neoplasia; 2012 Jul; 14(7):612-23. PubMed ID: 22904678 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]